For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

July 15, 2020

Published: July 15, 2020
Category: CCTG Bulletin

The CCTG Trialblazers raised $7200 as part of the Canadian Cancer Society's Relay For Life "At Home" event. 

Read More

Published: July 15, 2020
Category: CCTG Bulletin

CCTG investigators are contributing to COVID-19 research by developing and leading innovative, cutting-edge clinical trials to support patients with cancer.

Read More

Published: July 15, 2020
Category: CCTG Bulletin

Congratulations to the 2019-2020 New Investigator Cancer Trials Practicum graduates!

Read More

Published: July 15, 2020
Category: Trials

Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy.

Read More

Published: July 15, 2020
Category: Publications

There were four recent publications, including the primary publication for CCTG CO.26: A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients with Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies.

Read More

Published: July 15, 2020
Category: Other

The CCTG Connection will be on hiatus until the Fall.

Read More

July 08, 2020

Published: July 08, 2020
Category:

In the race to find new ways to prevent and treat COVID-19, the Canadian Cancer Trials Group (CCTG) has launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients.

The trial is called CCTG IC.8:  Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (COV-IMMUNO). IMM-101 is a preparation of safe, heat-killed bacteria that broadly stimulates the innate, or “first-response,” arm of the immune system. Researchers hope that boosting cancer patients’ immune systems with IMM-101 will protect them from developing severe COVID-19 and other dangerous lung infections.

Read More

June 24, 2020

CCTG is very pleased to announce that Dr. Sara Taylor is the 2020 recipient of the Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award.  

This award honours young investigators who have participated in the Investigational New Drug (IND) Program and have significantly contributed to IND trial conduct within their institution. Individuals are nominated by their colleagues and the IND Director/Executive Committee to determine the awardee.

Read More